December 22, 2024 - 14:43

Proprietary mutual funds may seem appealing due to their personalized approach and tailored investment strategies, but they come with significant drawbacks that investors should carefully consider before making any commitments. These funds are often managed by financial institutions that have a vested interest in promoting their own products, which can lead to conflicts of interest.
Investors may find themselves facing higher fees and expenses compared to non-proprietary options. Additionally, the limited range of investment choices can restrict diversification, potentially increasing risk. The performance of proprietary funds may also be influenced by the institution’s marketing strategies rather than pure investment merit, making it challenging for investors to gauge true performance.
Before investing in proprietary mutual funds, individuals should conduct thorough research and weigh the potential benefits against the inherent risks. Consulting with a financial advisor can provide valuable insights and help investors make informed decisions tailored to their financial goals.
August 29, 2026 - 00:42
Why Rubrik Stock Is Plummeting TodayShares of Rubrik took a sharp hit today, with the stock falling more than 12 percent in morning trading. The drop comes after the data security company reported quarterly results that showed a...
August 28, 2026 - 04:10
Michael Burry Thanks Tech Columnist’s Praise For Making ‘A Killing’ On NVDA, MSFT Calls Into EarningsInvestor Michael Burry, best known for betting against the housing market before the 2008 crash, has acknowledged a tech columnist`s compliment about his recent options trades. The acknowledgment...
August 27, 2026 - 21:27
Texas is on RBC's map to grow its City National Bank unitRoyal Bank of Canada is setting its sights on Texas as a key market for expanding its City National Bank subsidiary. Senior executives at the Toronto-based lender said they see strong organic...
August 27, 2026 - 11:07
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate UpdatesShanghai, August 26, 2026 - Shanghai Junshi Biosciences, a biopharmaceutical company focused on creating new treatments, has shared its financial results for the first half of 2026. The company...